Literature DB >> 9774597

Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays.

J M Raboud1, E Seminari, S L Rae, P R Harrigan, R S Hogg, B Conway, C Sherlock, M T Schechter, M V O'Shaughnessy, J S Montaner.   

Abstract

The costs of four algorithms for monitoring plasma human immunodeficiency virus type 1 RNA were compared. For patients with strong virologic responses, the use of Ultra Direct exclusively was the cheapest strategy. For patients with weak virologic responses, small savings could be obtained by using Amplicor and retesting only samples with values below 500 copies/ml with Ultra Direct.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9774597      PMCID： PMC105333     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

1.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1997-06-25       Impact factor: 56.272

2.  Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.

Authors:  R S Hogg; S A Rhone; B Yip; C Sherlock; B Conway; M T Schechter; M V O'Shaughnessy; J S Montaner
Journal:  AIDS       Date:  1998-02-12       Impact factor: 4.177

3.  HIV therapeutics.

Authors:  D D Richman
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

4.  A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity.

Authors:  J Mulder; R Resnick; B Saget; S Scheibel; S Herman; H Payne; R Harrigan; S Kwok
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

5.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

6.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Authors:  J S Montaner; P Reiss; D Cooper; S Vella; M Harris; B Conway; M A Wainberg; D Smith; P Robinson; D Hall; M Myers; J M Lange
Journal:  JAMA       Date:  1998-03-25       Impact factor: 56.272

7.  Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study.

Authors:  D Rouleau; B Conway; J Raboud; S Rae; S Fransen; A Shillington; C Zala; M V O'Shaughnessy; J S Montaner
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226
  7 in total
  2 in total

1.  Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5.

Authors:  T Elbeik; E Charlebois; P Nassos; J Kahn; F M Hecht; D Yajko; V Ng; K Hadley
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

2.  Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.

Authors:  Susanne May; Anthony Gamst; Richard Haubrich; Constance Benson; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.